ABBV Jan 2025 160.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 01:25PM EDT. Market open.
| Previous close | 13.15 |
| Open | 13.15 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 160.00 |
| Expiry date | 2025-01-17 |
| Day's range | 13.15 - 13.15 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.01k |
Simply Wall St.AbbVie Inc.'s (NYSE:ABBV) Intrinsic Value Is Potentially 57% Above Its Share Price
Key Insights AbbVie's estimated fair value is US$243 based on 2 Stage Free Cash Flow to Equity Current share price of...
ZacksAbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
AbbVie (ABBV) closed at $154.65 in the latest trading session, marking a +1.25% move from the prior day.
PR NewswireAbbVie Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma
AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. TEPKINLY is the first and only subcutaneous T-cell engaging bispecific antibody approved for the treatment of this patient population in the European Union (EU), as well as Liechtenste
© 2023 Yahoo. All rights reserved.
